VJOncology is committed to improving our service to you

ITOC 2020 | PD-1 and OX40: potential PDAC combination therapy

VJOncology is committed to improving our service to you

Cassian Yee

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the combination of PD-1 inhibitor with OX40 agonist which induced tumor rejection and immune memory in mice with pancreatic tumors. This information can be used in the development of future immune-based combination therapies for pancreatic ductal adenocarcinoma (PDAC). This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter